Stefan Hellbardt, PhD, and Degenhard Marx, PhD, focus their review on the trends in topical skin medication, the impact on primary packaging, and possible dispensing solutions.
In June’s edition of The Second Quadrant, we heard from leading excipient providers about challenges faced directly related to formulating with excipients for greater bioavailability.…
Drug Development Executive: Donald E. Morel, Jr., PhD, Chairman and CEO, West, discusses how the company works closely with pharmaceutical and biotechnology companies to deliver life-changing therapies safely and effectively to patients.
FORMULATION DEVELOPMENT – Amorphous Dispersion Formulation Development: Phase-Appropriate Integrated Approaches to Optimizing Performance, Manufacturability, Stability & Dosage Form
John Baumann, Dan Dobry, and Rod Ray, PhD, review the development and use of amorphous SDDs and the testing methodologies used to optimize the formulation and spray-drying process for performance, manufacturability, stability, and incorporation into final dosage forms.
Derek G. Hennecke concludes his 6-part series offering an overview of this year’s best business books with insights into what they can teach the Pharma industry.
PREDICTIVE MODELING – Predicting Price Changes of Oncology Drugs in the US: Can Proportional Hazard Models Predict the Timing & Percentage of Changes?
Bruce Wang, PhD, MA, suggests that Cox Proportional Hazard Models can be used to predict price change percentages and timing of prescription drugs in the market, which is extremely valuable as it enables more informed insights through predictive modeling and analytics on the lifecycle of a drug.
Derek G. Hennecke continues with part 5 on a new 6-part series offering an overview of this year’s best business books with insights into what they can teach the Pharma industry.
SPECIAL REPORT – Prefilled Syringes & Parenteral Contract Manufacturing: Improving for Flexibility & Customization
Special Feature: Contributor Cindy H. Dubin speaks with prefilled syringe manufacturers as well as contract parenteral manufacturers who share their thoughts about the delivery challenges associated with high-viscous, high-volume formulations.
FORMULATION DEVELOPMENT – Trends & Opportunities in Particle Design Technologies – Life Sciences & Biopharma in the Spotlight
Frost & Sullivan Analyst, Cecilia Van Cauwenberghe, MS, examines the observed trends in particle design and engineering technologies, as well as the main factors and opportunities driving the principal technological advances in the biopharmaceutical industry.
Derek G. Hennecke continues with part 4 of a new 6-part series offering an overview of this year’s best business books with insights into what they can teach the Pharma industry.
EXCLUSIVE ONLINE CONTENT
A pioneer in biotechnological medicines in Brazil, BIOMM is launching Nemera’s Advapen under the trade name Lifepen® for the administration of….
Recipharm Signs Memorandum of Understanding (MOU) for the Fill Finish of Vaccines & Biotherapeutics in Morocco
Global contract development and manufacturing organization (CDMO) Recipharm has recently signed an MOU, along with His Majesty the King of Morocco, Mohammed VI, the Moroccan Government and….
Genedata recently announced that Encoded Therapeutics has chosen Genedata Bioprocess to digitalize their proprietary gene therapy R&D technology…..
Evonik offers an innovative green technology that enables the large-scale synthesis of active pharmaceutical ingredients in water. The “Chemistry in Water” technology has the potential….
InMed Pharmaceuticals Signs Non-Binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids
InMed Pharmaceuticals Inc. recently announced it has entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of….